Golden Reserve Retirement LLC Buys New Holdings in Eli Lilly and Company $LLY

Golden Reserve Retirement LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,274 shares of the company’s stock, valued at approximately $1,369,000. Eli Lilly and Company comprises about 0.3% of Golden Reserve Retirement LLC’s portfolio, making the stock its 15th biggest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. 10Elms LLP boosted its holdings in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. Miller Global Investments LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $33,000. Finally, Hopwood Financial Services Inc. boosted its holdings in Eli Lilly and Company by 113.6% in the third quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after acquiring an additional 25 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a report on Tuesday, February 10th. Daiwa Securities Group boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, TD Cowen boosted their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,216.52.

Eli Lilly and Company Trading Up 0.7%

Shares of LLY opened at $874.14 on Wednesday. The stock’s 50-day moving average is $952.17 and its two-hundred day moving average is $986.25. The stock has a market cap of $825.91 billion, a PE ratio of 38.09, a P/E/G ratio of 1.03 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company earned $5.32 earnings per share. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Acquisition — Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, adding a Type II JAK2 inhibitor for myelofibrosis and expanding its hematology/oncology pipeline. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: AI drug‑discovery partnership — Lilly struck a deal with AI startup Profluent (reported as up to $2.25 billion), signaling investment in AI-enabled discovery that could accelerate new programs and cost efficiency. Emeryville AI Upstart Snags $2.25 Billion Gene Editing Deal With Eli Lilly
• Positive Sentiment: Analyst support — Multiple analysts and outlets have reiterated bullish views (e.g., Barclays Overweight with a $1,350 target), supporting the narrative that Lilly’s deal cadence and diversified pipeline justify higher valuation. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Sector tone — Health‑care stocks broadly edged higher midday, providing modest tailwinds for large-cap pharma names including LLY. Sector Update: Health Care Stocks Edge Higher Late Afternoon
• Neutral Sentiment: Near‑term earnings focus — Analysts are parsing Q1 guidance and launch metrics ahead of results; market reaction may hinge on GLP‑1 trends and margins. Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
• Negative Sentiment: GLP‑1 competitive pressure — Data and prescription tracking show Novo Nordisk’s oral Wegovy gaining share vs. Lilly’s oral competitor, raising concerns about Foundayo adoption and near‑term revenue growth. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: New competitor data — A late‑stage obesity trial from Boehringer/Ingelheim showed meaningful weight loss, intensifying competition in the obesity space where Lilly has been a market leader. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Short‑term pullback/volatility — Shares pulled back with the broader market ahead of earnings as investors weigh pricing pressure, rising costs and softer launch datapoints. Pharmaceutical Stock Pulling Back Before Earnings

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.